Nuvocid (oritavancin) / Melinta Therap, Novartis, Menarini - LARVOL DELTA

Open Label, Dose-finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Participants With Suspected or Confirmed Bacterial Infections (clinicaltrials.gov) - P1 | N=41 | Completed | Sponsor: Melinta Therapeutics, LLC | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Pediatrics

Long-Term Therapy with Long-Acting Lipoglycopeptide Antibiotics in the Treatment of Cardiovascular Prosthetic Infections: A Systematic Review. (PubMed, Antibiotics (Basel)) - "Background: Dalbavancin and oritavancin are long-acting lipoglycopeptides increasingly used off-label for a variety of Gram-positive infections. This systematic review was registered on Open Science Framework. This work was supported by grants from the Italian Ministry of Health through Ricerca Corrente, Linea 3, Progetto 3."

Journal • Review • Cardiovascular • Infectious Disease • Inflammation

ML-ORI-201: Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections (clinicaltrials.gov) - P2 | N=118 | Completed | Sponsor: Melinta Therapeutics, LLC | Recruiting ➔ Completed | N=75 ➔ 118

Enrollment change • Trial completion • Dermatology • Infectious Disease • Pediatrics • CRP

Difficult-to-Treat Skin and Soft Tissue Infections Caused by Panton-Valentine Leukocidin-Producing Community-Associated Methicillin-Resistant Staphylococcus aureus: A Case Series. (PubMed, Infect Dis Rep) - "Long-acting lipoglycopeptides (oritavancin or dalbavancin) were evaluated as therapeutic options to achieve clinical resolution. PVL-positive CA-MRSA infections are characterized by recurrence, intrafamilial clustering, and frequent therapeutic failure with standard oral agents. Effective management requires an integrated approach combining prompt surgical drainage; systemic therapy, preferably including long-acting lipoglycopeptides; and comprehensive decolonization of all close contacts."

Journal • Infectious Disease

Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies. (PubMed, Pharmacotherapy) - "Despite previous warnings, we found no evidence of ineffectiveness with ORI for OM. ORI's infrequent dosing schedule may provide convenience over daily parenteral therapy, particularly for difficult-to-treat pathogens like MRSA and VRE. Further research is needed to optimize dosing strategies based on pathogen susceptibility and establish appropriate therapeutic drug monitoring protocols."

Journal • Observational data • Retrospective data • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics

Comparative Analysis of Adverse Drug Reactions Between Oritavancin Diphosphate and Oritavancin-HPβCD Using FAERS Data. (PubMed, Hosp Pharm) - "Oritavancin, a lipoglycopeptide antibiotic, has emerged as a treatment alternative to vancomycin, especially in light of rising resistance. Both formulations are considered safe, consistent with their product information. These findings highlight the need for formulation-specific safety considerations and standardized protocols in clinical practice."

Adverse drug reaction • Journal • Dermatology • Immunology • Infectious Disease • Movement Disorders • Pediatrics • Pruritus • Urticaria

Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes. (PubMed, BMC Infect Dis) - No abstract available

Journal • Infectious Disease

In vitro and in vivo efficacy of vancomycin against Elizabethkingia species and the impact of increased vancomycin MICs. (PubMed, Microbiol Spectr) - "Vancomycin improved Galleria mellonella survival in a dose-dependent manner, whereas teicoplanin, dalbavancin, oritavancin, and daptomycin were ineffective...Most commonly considered agents, including fluoroquinolones, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole, are increasingly compromised by resistance, toxicity, or inconsistent efficacy...These findings suggest vancomycin may offer therapeutic benefit when no preferred options are available. They support cautious use in selected cases and highlight the need for continued monitoring of susceptibility and resistance development."

Journal • Preclinical • Infectious Disease

ORItavancin as a therapeutic regimen for Cardiac Implantable Electronic Devices infections with multidrug-resistant Gram-positive cocci (ORI-4-CIEDi) pilot study: rationale and design. (PubMed, Cardiol J) - No abstract available

Journal • Cardiovascular • Dermatology • Infectious Disease

Medical Source Control with Oritavancin in Complicated Gram-positive Bacterial Infections: A Case Series. (PubMed, Int J Infect Dis) - "These findings suggest it may serve as an effective medical alternative to source control in frail, difficult-to-treat populations."

Journal • Infectious Disease

ML-ORI-201: Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infections (clinicaltrials.gov) - P2 | N=75 | Recruiting | Sponsor: Melinta Therapeutics, LLC | N=200 ➔ 75

Enrollment change • Dermatology • Infectious Disease • Pediatrics • CRP

Emerging Antimicrobial Strategies Against Heterogeneous and Vancomycin-Intermediate Staphylococcus aureus. (PubMed, Int J Gen Med) - "Conventional monotherapies, including daptomycin and linezolid, are often compromised by cross-resistance and inconsistent efficacy...Novel antimicrobials, such as next-generation glycopeptides (LY333328, oritavancin, YV4465), synthetic agents (pyridyl disulfides, alpha-amyrin), and natural derivatives (plant flavonoids, cyanobacterial metabolites), have demonstrated enhanced activity against VISA/hVISA by disrupting membranes, suppressing virulence, or reversing resistance...Despite these promising advances, clinical translation remains challenging, requiring rigorous validation of synergistic mechanisms, optimized dosing strategies, and resistance mitigation approaches. Continued innovation in antimicrobial development is essential to address the growing threat of multidrug-resistant Staphylococcus aureus infections."

Heterogeneity • Journal • Review • Infectious Disease

Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review. (PubMed, Pharmaceuticals (Basel)) - "In vitro data demonstrated strong activity of oritavancin against methicillin-resistant Staphylococcus aureus and S. epidermidis biofilms, particularly in synergy with rifampin. Oritavancin represents a promising adjunct or alternative to conventional antimicrobial regimens in PJIs, particularly for outpatient management or in patients with multidrug-resistant Gram-positive infections. Further prospective studies are needed to define its role, optimal dosing, and long-term efficacy in this complex clinical setting."

Journal • Review • Infectious Disease • Orthopedics

A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges? (PubMed, Infect Dis Ther) - "Both agents share broad-spectrum activity against multidrug-resistant pathogens, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant strains, yet differ markedly in pharmacokinetics, pharmacodynamics, resistance profiles, and clinical adoption. Furthermore, we explore resistance development, drug-drug interaction profiles, and outpatient utility, providing actionable insights for optimizing treatment strategies. These findings underscore the need for tailored clinical integration of dalbavancin and oritavancin and spotlight their potential roles in future antimicrobial stewardship frameworks."

Journal • Review • Cardiovascular • Infectious Disease • Inflammation

Is There an Optimal Dosing Strategy for Dalbavancin and Oritavancin in Deep-Seated Infections? (IDWeek 2025) - No abstract available

Infectious Disease

One-Shot, One Opportunity: Retrospective Observational Study on Long-Acting Antibiotics for SSTIs in the Emergency Room-A Real-Life Experience. (PubMed, Pathogens) - "LALs appear effective and well-tolerated in the ER setting, supporting early discharge and reducing healthcare burden. Broader use may require structured care pathways and multidisciplinary coordination."

Journal • Observational data • Retrospective data • Infectious Disease

ML-ORI-201: Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin (clinicaltrials.gov) - P2 | N=200 | Recruiting | Sponsor: Melinta Therapeutics, LLC | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial primary completion date • Infectious Disease • Pediatrics • CRP

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections (clinicaltrials.gov) - P1 | N=52 | Recruiting | Sponsor: Melinta Therapeutics, LLC | Trial completion date: Jun 2025 ➔ Dec 2025 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Infectious Disease • Pediatrics

Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections (clinicaltrials.gov) - P1 | N=41 | Active, not recruiting | Sponsor: Melinta Therapeutics, LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pediatrics

Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center? (PubMed, Fed Pract) - "The cost of using oritavancin and dalbavancin was lower than that of vancomycin and daptomycin, especially for osteomyelitis. As safety and effectiveness data continue to emerge, the use of long-acting lipoglycopeptides appears to be an increasingly attractive alternative to traditional outpatient antimicrobial therapy."

HEOR • Journal • Infectious Disease • Inflammation

The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus spp. (PubMed, Open Forum Infect Dis) - "Oritavancin is emerging as a potential alternative to standard antibiotic regimens in the treatment of infective endocarditis caused by gram-positive bacteria, though evidence remains limited. We hereby report 7 cases of enterococcal endocarditis treated with oritavancin as consolidation therapy, resulting in 6 cures and 1 relapse."

Clinical • Journal • Cardiovascular • Infectious Disease

Long-acting lipoglycopeptides compared to standard-of-care for the treatment of complicated gram-positive infections: a systematic review and meta-analysis. (PubMed, Int J Antimicrob Agents) - "LA-LGP for treatment of complicated gram-positive infections resulted in similar efficacy and safety to SOC antibiotics and may be a reasonable alternative for such infections. Results should be interpreted with caution given the risk of bias and heterogeneity.(PROSPERO Registration ID: CRD42024532465)."

Journal • Retrospective data • Cardiovascular • Infectious Disease • Inflammation

Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study. (PubMed, Open Forum Infect Dis) - "Oritavancin is promising as a suitable and potentially cost-effective alternative for patients with SAB who are ineligible for OPAT. Prospective studies are required to confirm its utility in clinical practice, in particular in patients who do not receive oral antibiotic stepdown therapy."

Clinical • Journal • Retrospective data • Cardiovascular • Infectious Disease • Inflammation

i-DENV: development of QSAR based regression models for predicting inhibitors targeting non-structural (NS) proteins of dengue virus. (PubMed, Front Pharmacol) - "Model robustness was supported through scatter plots, chemical clustering, statistical analyses, decoy set etc. Virtual screening identified Micafungin, Oritavancin, and Iodixanol as top hits for NS2B/NS3 protease, and Cangrelor, Eravacycline, and Baloxavir marboxil for NS5 polymerase. However, further in vitro and in vivo studies are essential to validate their therapeutic potential. The i-DENV web server is freely accessible at http://bioinfo.imtech.res.in/manojk/idenv/, offering a structure-specific drug prediction platform for DENV research and antiviral drug discovery."

Journal • Dengue Fever

Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option? (PubMed, J Antimicrob Chemother) - No abstract available

Journal • Cardiovascular